Clinical trials: Thymoma, open to volunteers
Ocular Myasthenia Gravis
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).
- Trial name
- TREAT-OMG (NCT04182984)
- Testing
- Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Unresectable Thymic Carcinoma
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic…
- Trial name
- XANTHOS (NCT07750353)
- Testing
- Sacituzumab Tirumotecan (Sac-TMT)
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Myasthenia Gravis
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
It is evidenced that efgartigimod can rapidly and significantly improve the symptoms of myasthenia gravis. The global multicenter clinical trials hace confirmed that efgartigimod is safe and well tolerated.
- Trial name
- NCT06221501
- Testing
- Efgartigimod Alfa
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Thymic Epithelial Tumor, Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer
- Trial name
- NCT05667948
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Thymoma
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.
- Trial name
- NCT02633553
- Testing
- adjuvant radiotherapy
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Fudan University
Thymic Epithelial Tumor, Radiotherapy Side Effect
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection.
- Conditions
- Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
- Trial name
- NCT06311955
- Testing
- Carbon ion radiotherapy, combined with platinum-based regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Thymoma
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
- Trial name
- NCT06730308
- Testing
- Radiotherapy, Concurrent chemotherapy, Methylprednisolone
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Thymic Epithelial Tumor, Thymic Carcinoma
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymoma, Thymoma and Thymic Carcinoma
- Trial name
- INTHYM (NCT06301945)
- Testing
- Artificial Intelligence Diagnostics, Recurrence Prediction Tool
- Where
- Netherlands
- Volunteers
- 1,020 people
- Sponsor
- Erasmus Medical Center
Thymoma and Thymic Carcinoma, Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors.
- Conditions
- Thymoma and Thymic Carcinoma, Thymoma, Thymic Cancer, Thymic Epithelial Tumor
- Trial name
- NCT06692062
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Rongrong Zhou
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Thymic Carcinoma, Thymoma
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy.
- Trial name
- NCT06838910
- Testing
- Experimental: tislelizumab+anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Thymoma Malignant Recurrent
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.
- Trial name
- RADIO-RYTHMIC (NCT04731610)
- Testing
- Radiotherapy, Surveillance after resection
- Where
- 21 sites in France
- Volunteers
- 314 people
- Sponsor
- Institut Curie
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities…
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma, Thymoma
- Trial name
- TAILOR-MG (NCT07571525)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS San Raffaele
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Thymoma
Robot-assisted vs VATS for Thymoma
The aim of this study is to explore the advantages of robot-assisted thymectomy in long-term survival benefits and short-term clinical efficacy compared with video-assisted thoracoscopic thymectomy based on a multi-center…
- Trial name
- NCT06029621
- Testing
- RATS for Thymectomy, VATS for Thymectomy
- Where
- 2 sites in China
- Volunteers
- 304 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Thymic Epithelial Tumor, Recurrent Thymoma
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT05104736
- Testing
- PT-112
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)